From: Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
Item
Target AEs
Other AEs
Sums
Target drug
a
b
a + b
Other drugs
c
d
c + d
a + c
b + d
a + b + c + d